Drugs / Nicotine polacrilex lozenge
Nicotine polacrilex lozenge
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT02069392 Comparator | Jan 2015 → Jun 2017 | schizoaffective disorder, schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicotine polacrilex lozenge | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02069392 ↗ |
| Known as | Nicorette polacrilex lozenges, GlaxoSmithKline, 2 mg and 4 mg | “Nicorette polacrilex lozenges, GlaxoSmithKline, 2 mg and 4 mg” NCT02069392 ↗ |
| Route | Oral | “participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.” NCT02069392 ↗ |